-
by
MedPAC Staff
| Jun 16, 2016
When the Commission began its deliberations on drug policy, which ultimately shaped the contents of the June report, it started with two informational presentations that were intended to provide background and context for its discussions. The Commission is now releasing annotated versions of these presentations to serve as a resource for policymakers.
Full post
-
by
MedPAC Staff
| Jan 27, 2016
Evidence suggests that price growth for brand-name drugs is beginning to drive growth in average prices of all drugs covered under Part D.
Full post
-
by
MedPAC Staff
| Oct 22, 2014
At MedPAC’s October public meeting, the Commission discussed patterns of potentially inappropriate opioid use in Medicare’s prescription drug benefit, Part D. In 2011, 10 million beneficiaries, or about 32 percent of Part D enrollees filled at least one prescription for an opioid. The share of Part D enrollees who use opioids in varies considerably across states.
Full post